About this episode
Glenmark Chairman and Managing Director Glen Saldanha joins Vikas Dandekar and Rica Bhattacharyya to discuss the company’s 25-year innovation bet, and why it’s finally paying off. At the center is ISB2001, a tri-specific antibody partnered with AbbVie, born out of Glenmark’s IGI platform after fifteen years of R&D. Saldanha talks through the platform’s pipeline, why Glenmark stays out of ADCs and CAR-T, how it’s building “Glenmark 3.0” across oncology, dermatology and respiratory, and why he still rates the US well ahead of China on innovation. The conversation also covers India’s licensing deals with Chinese biotechs, AI in drug discovery, and the GLP-1 market.
Listen in
You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin
Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard, From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks and much more.
Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time The Morning Brief publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Morning Brief
J.P.Morgan’s Anu Aiyengar on Mega Deals, AI’s Banking Reset and the India Bet
The Morning Brief
ET Deep Dive: When Development Turns Disaster
The Morning Brief
Subrata Mitra on India’s VC Reset, the AI Capital Race and What Comes Next
The Morning Brief
HDFC Bank’s CEO Hunt
The Morning Brief